Search the Studies

15 Studies found from all possible combinations of your search terms. Select a protocol that you wish to review.
Protocol Number Title Protocol Status Min-Max Age Institute Keywords
001859-CA Phase I Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent GlioblastomaRecruitment has not started18-120 YearsNCI Glioblastoma
21-C-0015Phase II Trial Evaluating the Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment with Immune Checkpoint Inhibition (ICI) in Patients with Newly Diagnosed Glioblastoma or GliosarcomaParticipants currently recruited/enrolled18-125 YearsNCI Glioblastoma
20-C-0069A First-In-Human Phase I Single-Agent Dose-Escalation and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System NeoplasmsParticipants currently recruited/enrolled18-125 YearsNCI Glioblastoma
20-C-0027A Phase I Clinical Trial of Selinexor (KPT-330) in Combination with Temozolomide and Radiation Therapy in Patients with Newly Diagnosed GlioblastomaParticipants currently recruited/enrolled18-125 YearsNCI Glioblastoma
19-C-0006Phase II Trial Evaluating Nivolumab In Patients With IDH-Mutant Gliomas With And Without Hypermutator PhenotypeParticipants currently recruited/enrolled18-125 YearsNCI Glioblastoma
18-N-0077Cytokine Microdialysis For Real Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint BlockadeCompleted Study; data analyses ongoing18-125 YearsNINDSGlioblastoma
18-C-0080Feasibility and Preliminary Efficacy of an Enhanced Mindfulness Intervention for Children and Young Adults with High Grade or High-Risk Cancer and Their Caregivers: A Pilot Randomized Controlled TrialCompleted Study; data analyses ongoing5-125 YearsNCI Glioblastoma
17-C-0037Phase II Trial of LB100, a Protein Phosphatase 2A Inhibitor, in Recurrent GlioblastomaCompleted Study; data analyses ongoing18-125 YearsNCI Glioblastoma
17-C-0034A Randomized, Double Blind Phase II Trial of Surgery, Radiation Therapy Plus Temozolomide and Pembrolizumab with and without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)Completed Study; data analyses ongoing18-125 YearsNCI Glioblastoma
17-C-0009Phase I Trial of Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide (tmz) Followed by Randomized Phase II Trial of Zotiraciclib (TG02) plus Temozolomide versus Temozolomide alone in Adults with Recurrent Anaplastic Astrocytoma and GlioblastomCompleted Study; data analyses ongoing18-125 YearsNCI Glioblastoma
16-C-0081A Phase I Dose Escalation Trial of Re-Irradiation in Good Prognosis Recurrent GlioblastomaCompleted Study; data analyses ongoing18-125 YearsNCI Glioblastoma
16-C-0034A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior BevacizumabCompleted Study; data analyses ongoing18-125 YearsNCI Glioblastoma
16-C-0011A Phase I-II Trial of Everolimus and Sorafenib in Patients with Recurrent High-Grade GliomasCompleted Study; data analyses ongoing18-125 YearsNCI Glioblastoma
10-C-0166A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of PembrolizumabParticipants currently recruited/enrolled18-72 YearsNCI Glioblastoma
04-C-0200Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for RecurrenceParticipants currently recruited/enrolled18-125 YearsNCI Glioblastoma